Subscribe for the latest consumer trends, trade news, nutrition science and regulatory updates in the supplement industry!
Join 37,000+ members. Yes, it's completely free.
Triarco Industries Inc. 39906
April 26, 2004
1 Min Read
Triarco Industries Inc.
Alphastat Reduces Circulating Dihydrotestosterone (DHT) Levels in aPreliminary Clinical Trial
WAYNE,N.J.Alphastat is patented for inhibiting the enzyme 5areductase. Thisultimately reduces levels of dihydrotestosterone (DHT), which has been reportedfor symptoms of benign prostate hyperplasia (BPH) and androgenetic alopecia.Mark L. Anderson, Ph.D., Triarcos director of research and development, willdiscuss the results of a preliminary three-month clinical trial showing theeffect of Alphastat on DHT levels.
The VendorWorks presentation will be given Thursday, May 6, from 10 to 10:50a.m. at SupplySide East. For additional information, visit www.triarco.com.
You May Also Like